NASDAQ:ENOB
Delisted
Enochian Biosciences Inc. Stock News
$0.700
+0 (+0%)
At Close: Nov 24, 2023
Enochian BioSciences Announces the Appointment of Executive Vice President of Research and Development with 25 years of Industry Experience
11:00am, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
LOS ANGELES, April 20, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases
The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More
12:24pm, Thursday, 07'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
AstraZeneca In-Licenses Preclinical Bispecific Antibody Candidate From Harbour BioMed For Up To $350M
Enochian BioSciences Announces Appointment of Senior Vice President for Clinical Operations with 32 Years’ Experience at Pfizer
10:00am, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
LOS ANGELES, April 07, 2022 (GLOBE NEWSWIRE) -- Enochian BioSciences, Inc., (NASDAQ: ENOB), a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announc
Enochian BioSciences Inventor and Co-Founder Presents Data on Novel Clinical Approaches as the Invited, Concluding Plenary Speaker at the Innate Killer Summit
10:00am, Tuesday, 05'th Apr 2022 GlobeNewswire Inc.
LOS ANGELES, April 05, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announce
Enochian BioSciences, Inc.: Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
12:05pm, Friday, 03'rd Dec 2021 FinanzNachrichten
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
12:00pm, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, toda
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid Tumors
12:00pm, Friday, 03'rd Dec 2021 Intrado Digital Media
LOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma.
Vanguard Group Inc. Sells 52,662 Shares of Enochian Biosciences, Inc. (NASDAQ:ENOB)
09:14am, Saturday, 27'th Nov 2021 Transcript Daily
Vanguard Group Inc. reduced its stake in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 16.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,656 shares of the companys stock after selling 52,662 shares during the period. Vanguard Group Inc.s holdings in Enochian Biosciences were worth []
ENOB Stock: Why The Price Increased Today
08:33am, Monday, 18'th Oct 2021
The stock price of Enochian Biosciences Inc (NASDAQ: ENOB) increased by over 3% pre-market today. This is why it happened.
Company encouraged by clear path to IND in near-term following its review of the FDA's Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-ter
Scientific Advisory Board Member Resigns Due to Conflict with Responsibilities with Important Public Sector Entity
06:00pm, Friday, 15'th Oct 2021
LOS ANGELES, Oct. 15, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced t
Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
06:00pm, Tuesday, 12'th Oct 2021
LOS ANGELES, Oct. 12, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announ
Enochian BioSciences Announces Its Successful Completion of FDA Pre-IND for a Potential Cure for Hepatitis B Virus Infection
07:00am, Monday, 27'th Sep 2021
Company encouraged by clear path following review of FDA's CBER written comments Company encouraged by clear path following review of FDA's CBER written comments
LOS ANGELES, Aug. 30, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene-modified cellular and immune therapies for infectious diseases and cancer, announced t
Distinguished Scientific and Clinical Leader to Join Enochian BioSciences' Hepatitis B Cure Scientific Advisory Board
10:18am, Monday, 23'rd Aug 2021
LOS ANGELES, Aug. 23, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) – Enochian BioSciences, a company focused on gene modified cellular and immune therapies for infectious diseases and cancer, announced t
